+
Site Tour

Search

Showing 31 - 40 of 532 results.

  • Patients who benefit

    A STATE-OF-THE-ART TREATMENT OPTION FOR PATIENTS AT HIGH RISK FOR SURGERY TriClip TEER is a low-risk,11 non-surgical treatment option for improving quality of life and functional status in patients w

  • Features - G4

    The TriClip™ G4 Transcatheter Edge-to-Edge Repair System empowers you with stable navigation and precise delivery2 for complex conditions.

  • Features - G5

    CONTROL MEETS EFFICIENCYTRICLIP™ G5 The TriClip™ G5 Transcatheter Edge-to-Edge Repair System empowers you with stable navigation and precise delivery for complex conditions. G5 TEER BROCHURE  

  • Features - G4

    MITRACLIP™ SUCCESSFULLY TREATS A BROAD RANGE OF VALVE ANATOMIES IN REAL-WORLD USE8,9   NEARLY 1 IN 5 PATIENTS TREATED HAVE VALVE ANATOMIES CONSIDERED COMPLEX8 Valve anatomies include: presence

  • Patients who benefit

    49% of patients with symptomatic severe MR were not operated due to age, co-morbidities, or impaired LV.5 If left untreated, MR initiates a cascade of events leading to death, with 1-year mortali

  • TAVI Summit 2025

    ON DEMAND - TAVI SUMMIT 2025 3rd Abbott Annual Transcatheter Aortic Valve Implantation Summit SESSION 1: BEYOND THE TAVI IMPLANT: A STRATEGIC APPROACH TO LIFETIME MANAGEMENT SESSION 2: OPTIMIZING

  • LAAO Summit 2025

    ON DEMAND - LAAO SUMMIT 2025 14th International Left Atrial Appendage Occlusion Summit SESSION 1: PATIENT SELECTION & PRE-PROCEDURAL PLANNING SESSION 2: PROCEDURAL OPTIMIZATION & IMAGING TECHNIQUE

  • Features

    SWITCH TO THE REFERRAL VIEW    For more information specific to neurology regarding LAA Occlusion

  • Overview

    LEARN MORE: AMPLATZER™ TALISMAN™ PFO OCCLUDER Clinical data Diagnosis  Prevention PFO CLOSURE: BEHIND THE NUMBERS Ischemic strokes are of unknown cause5 Of patients with an isch

  • Overview

    SWITCH TO THE interventional VIEW    For more information specific to interventional cardiology regarding PDA closure If PDA is left untreated, the mortality rate is 20% by age 20 years,

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline